
Cibus, Inc. (NASDAQ:CBUS – Free Report) – Equities researchers at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for Cibus in a report issued on Friday, November 13th. HC Wainwright analyst A. Dayal now forecasts that the company will post earnings per share of ($1.18) for the year, down from their previous forecast of ($1.13). The consensus estimate for Cibus’ current full-year earnings is ($1.13) per share. HC Wainwright also issued estimates for Cibus’ Q4 2026 earnings at ($0.28) EPS, FY2027 earnings at ($1.10) EPS, FY2028 earnings at ($1.12) EPS and FY2029 earnings at ($0.53) EPS.
Cibus (NASDAQ:CBUS – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.09). Cibus had a negative return on equity of 363.93% and a negative net margin of 2,131.38%. The business had revenue of $0.80 million during the quarter, compared to analysts’ expectations of $1.30 million.
CBUS has been the topic of several other research reports. Wall Street Zen cut shares of Cibus from a “hold” rating to a “sell” rating in a report on Saturday, October 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Cibus in a research note on Friday, September 25th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $9.00.
View Our Latest Analysis on CBUS
Cibus Price Performance
CBUS opened at $1.20 on Tuesday. The firm has a 50 day moving average price of $1.43 and a 200-day moving average price of $1.82. Cibus has a twelve month low of $1.02 and a twelve month high of $4.19.
Hedge Funds Weigh In On Cibus
Several institutional investors have recently made changes to their positions in CBUS. Dimensional Fund Advisors LP purchased a new position in shares of Cibus in the first quarter worth approximately $33,000. Nautilus Advisors LLC purchased a new stake in Cibus during the third quarter valued at approximately $35,000. Rockland Trust Co. purchased a new stake in Cibus during the second quarter valued at approximately $41,000. StoneX Group Inc. increased its holdings in Cibus by 115.9% during the third quarter. StoneX Group Inc. now owns 30,605 shares of the company’s stock valued at $50,000 after buying an additional 16,430 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp bought a new position in Cibus in the first quarter worth approximately $66,000. Institutional investors own 33.81% of the company’s stock.
Cibus Company Profile
Cibus is an agricultural technology company that develops plant traits using gene-editing technologies. Its proprietary Rapid Trait Development System (RTDS) is designed to make precise changes to a plant’s own genes, with the goal of developing useful crop characteristics without adding foreign DNA. The company’s research and development focuses on traits for crops including canola, rice and wheat, such as herbicide tolerance and resistance to crop diseases. Cibus aims to bring these traits to market through seed and technology licensing arrangements with partners in the agricultural industry.
Read More
- Five stocks we like better than Cibus
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Cibus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cibus and related companies with MarketBeat.com's FREE daily email newsletter.
